Syngen Biotech Co., Ltd. AI Stock Analysis
Syngen Biotech Co., Ltd. (8279) AI Stock Analysis
Syngen Biotech Co., Ltd.
(TPEx:8279)
The overall score of 56 reflects a company with a solid financial foundation but facing significant operational headwinds. The primary drag is the severe revenue contraction highlighted in the income statement, which is confirmed by a bearish technical trend with the stock trading below all major moving averages. These weaknesses are partially offset by a very strong, low-debt balance sheet and an attractive valuation with a low P/E and high dividend yield, which may provide a floor for the stock.
Syngen Biotech Co., Ltd. (8279) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 2.15B
- Dividend Yield
- 6.31%
- Average Volume (3M)
- 40.93K
- Price to Earnings (P/E)
- 10.5
- Beta (1Y)
- 0.19
- Revenue Growth
- -3.92%
- EPS Growth
- -29.93%
- Country
- TW
- Employees
- 554
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Syngen Biotech Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 1988 and based in Tainan City, Taiwan, Syngen Biotech Co.,Ltd. operates globally, including in Taiwan and China, specializing in the research, development, production, and sale of a diverse array of products. Its core offerings include...
Syngen Biotech Co., Ltd. Financial Statement Overview
Summary
Financial performance is mixed. A strong balance sheet (Score: 78) with low debt provides stability, but the income statement (Score: 35) shows a sharp 24.7% revenue decline and margin compression. Cash flow (Score: 65) is adequate but inconsistent. The overall financial health is weighed down significantly by deteriorating top-line growth.
Income Statement
35NegativeBalance Sheet
78PositiveCash Flow
65Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.05B | 2.14B | 2.01B | 1.84B | 1.93B | 1.47B |
| Gross Profit | 635.67M | 723.59M | 723.94M | 643.92M | 688.15M | 528.34M |
| EBITDA | 333.78M | 448.31M | 423.57M | 442.14M | 448.88M | 380.42M |
| Net Income | 204.72M | 271.59M | 240.21M | 274.83M | 321.24M | 237.77M |
Balance Sheet | ||||||
| Total Assets | 3.14B | 3.05B | 3.08B | 3.11B | 3.07B | 2.42B |
| Cash, Cash Equivalents and Short-Term Investments | 322.49M | 275.46M | 341.93M | 366.89M | 246.05M | 314.80M |
| Total Debt | 338.68M | 315.59M | 544.80M | 681.76M | 786.53M | 236.08M |
| Total Liabilities | 735.85M | 674.89M | 848.52M | 974.63M | 1.08B | 644.16M |
| Stockholders Equity | 2.40B | 2.37B | 2.24B | 2.13B | 1.99B | 1.77B |
Cash Flow | ||||||
| Free Cash Flow | 319.45M | 243.07M | 283.70M | 321.33M | -307.23M | 274.83M |
| Operating Cash Flow | 401.93M | 319.48M | 348.04M | 415.13M | 277.48M | 336.50M |
| Investing Cash Flow | -82.75M | -76.83M | -84.53M | -93.68M | -585.05M | -336.07M |
| Financing Cash Flow | -280.34M | -309.47M | -289.09M | -200.54M | 238.75M | -108.88M |
Syngen Biotech Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TW:8279, the sentiment is Negative. The current price of 79.30 is below the 20-day moving average (MA) of 80.90, below the 50-day MA of 80.02, and below the 200-day MA of 93.34, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 42.41 is Neutral, neither overbought nor oversold. The STOCH value of 27.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TW:8279.
Syngen Biotech Co., Ltd. Peers Comparison
Overall Rating
TW:843286Outperform
TW:827956Neutral
TW:410847Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 86Outperform | TWD 2.36B | 11.24 | ― | 4.25% | 20.56% | 67.85% | |
| 56Neutral | TWD 2.15B | 10.47 | ― | 6.31% | -3.92% | -29.93% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 47Neutral | TWD 2.02B | -74.69 | ― | ― | 1.10% | 54.83% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:8279 | Syngen Biotech Co., Ltd. | 79.30 | -43.38 | -35.36% | |
| TW:4108 | Phytohealth Corporation | 10.15 | -3.85 | -27.50% | |
| TW:6932 | Merdury Biopharmaceutical Corporation | 5.21 | -4.58 | -46.78% | |
| TW:7731 | MARX Biotech Co., Ltd. | 4.07 | -0.80 | -16.36% | |
| TW:7860 | Teh Seng Pharmaceutical Mfg Co Ltd | 77.70 | 10.18 | 15.07% | |
| TW:8432 | TSH Biopharm Corp. Ltd. | 61.40 | 11.86 | 23.94% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 18, 2026
